Simple method for the determination of rosiglitazone in human plasma using a commercially available internal standard

To the best of our knowledge, bioanalytical methods to determine rosiglitazone in human plasma reported in literature use internal standards that are not commercially available. Our purpose was to develop a simple method for the determination of rosiglitazone in plasma employing a commercially available internal standard (IS). After the addition of celecoxib (IS), plasma (0.25 mL) samples were extracted into ethyl acetate. The residue after evaporation of the organic layer was dissolved in 750 µL of mobile phase and 50 µL was injected on to HPLC. The separation was achieved using a Hichrom KR 100, 250 × 4.6 mm C 18 with a mobile phase composition potassium dihydrogen phosphate buffer (0.01 m , pH 6.5):acetonitrile:methanol (40:50:10, v/v/v). The ow‐rate of the mobile phase was set at 1 mL/min. The column eluate was monitored by uorescence detector set at an excitation wavelength of 247 nm and emission wavelength of 367 nm. Linear relationships ( r 2 > 0.99) were observed between the peak area ratio rosiglitazone to IS vs rosiglitazone concentrations across the concentration range 5–1000 ng/mL. The intra‐run precision (%RSD) and accuracy (%Dev) in the measurement of rosiglitazone were <±10.69 and <−12.35%, respectively across the QC levels (50–1000 ng/mL). The extraction efciency was >80% for both rosiglitazone and IS from human plasma. The lower limit of quantitation of the assay was 5 ng/mL. In summary, the methodology for rosiglitazone measurement in plasma was simple, sensitive and employed a commercially available IS. Copyright © 2003 John Wiley & Sons, Ltd.